Skip to main content
Top
Published in: Molecular Neurodegeneration 1/2012

Open Access 01-12-2012 | Methodology

Measurement of apolipoprotein E and amyloid β clearance rates in the mouse brain using bolus stable isotope labeling

Authors: Jacob M Basak, Jungsu Kim, Yuriy Pyatkivskyy, Kristin R Wildsmith, Hong Jiang, Maia Parsadanian, Bruce W Patterson, Randall J Bateman, David M Holtzman

Published in: Molecular Neurodegeneration | Issue 1/2012

Login to get access

Abstract

Background

Abnormal proteostasis due to alterations in protein turnover has been postulated to play a central role in several neurodegenerative diseases. Therefore, the development of techniques to quantify protein turnover in the brain is critical for understanding the pathogenic mechanisms of these diseases. We have developed a bolus stable isotope-labeling kinetics (SILK) technique coupled with multiple reaction monitoring mass spectrometry to measure the clearance of proteins in the mouse brain.

Results

Cohorts of mice were pulse labeled with 13 C6-leucine and the brains were isolated after pre-determined time points. The extent of label incorporation was measured over time using mass spectrometry to measure the ratio of labeled to unlabeled apolipoprotein E (apoE) and amyloid β (Aβ). The fractional clearance rate (FCR) was then calculated by analyzing the time course of disappearance for the labeled protein species. To validate the technique, apoE clearance was measured in mice that overexpress the low-density lipoprotein receptor (LDLR). The FCR in these mice was 2.7-fold faster than wild-type mice. To demonstrate the potential of this technique for understanding the pathogenesis of neurodegenerative disease, we applied our SILK technique to determine the effect of ATP binding cassette A1 (ABCA1) on both apoE and Aβ clearance. ABCA1 had previously been shown to regulate both the amount of apoE in the brain, along with the extent of Aβ deposition, and represents a potential molecular target for lowering brain amyloid levels in Alzheimer's disease patients. The FCR of apoE was increased by 1.9- and 1.5-fold in mice that either lacked or overexpressed ABCA1, respectively. However, ABCA1 had no effect on the FCR of Aβ, suggesting that ABCA1 does not regulate Aβ metabolism in the brain.

Conclusions

Our SILK strategy represents a straightforward, cost-effective, and efficient method to measure the clearance of proteins in the mouse brain. We expect that this technique will be applicable to the study of protein dynamics in the pathogenesis of several neurodegenerative diseases, and could aid in the evaluation of novel therapeutic agents.
Appendix
Available only for authorised users
Literature
1.
go back to reference Ong SE, Mann M: Mass spectrometry-based proteomics turns quantitative. Nat Chem Biol. 2005, 1: 252-262. 10.1038/nchembio736.CrossRefPubMed Ong SE, Mann M: Mass spectrometry-based proteomics turns quantitative. Nat Chem Biol. 2005, 1: 252-262. 10.1038/nchembio736.CrossRefPubMed
2.
go back to reference Doherty MK, Beynon RJ: Protein turnover on the scale of the proteome. Expert Rev Proteomics. 2006, 3: 97-110. 10.1586/14789450.3.1.97.CrossRefPubMed Doherty MK, Beynon RJ: Protein turnover on the scale of the proteome. Expert Rev Proteomics. 2006, 3: 97-110. 10.1586/14789450.3.1.97.CrossRefPubMed
3.
go back to reference Holtzman DM, Morris JC, Goate AM: Alzheimer’s disease: the challenge of the second century. Sci Transl Med. 2011, 3: 77sr71- Holtzman DM, Morris JC, Goate AM: Alzheimer’s disease: the challenge of the second century. Sci Transl Med. 2011, 3: 77sr71-
4.
go back to reference Goedert M: Alpha-synuclein and neurodegenerative diseases. Nat Rev Neurosci. 2001, 2: 492-501. 10.1038/35081564.CrossRefPubMed Goedert M: Alpha-synuclein and neurodegenerative diseases. Nat Rev Neurosci. 2001, 2: 492-501. 10.1038/35081564.CrossRefPubMed
5.
go back to reference DiFiglia M, Sapp E, Chase KO, Davies SW, Bates GP, Vonsattel JP, Aronin N: Aggregation of huntingtin in neuronal intranuclear inclusions and dystrophic neurites in brain. Science. 1997, 277: 1990-1993. 10.1126/science.277.5334.1990.CrossRefPubMed DiFiglia M, Sapp E, Chase KO, Davies SW, Bates GP, Vonsattel JP, Aronin N: Aggregation of huntingtin in neuronal intranuclear inclusions and dystrophic neurites in brain. Science. 1997, 277: 1990-1993. 10.1126/science.277.5334.1990.CrossRefPubMed
6.
go back to reference Trojanowski JQ, Dickson D: Update on the neuropathological diagnosis of frontotemporal dementias. J Neuropathol Exp Neurol. 2001, 60: 1123-1126.PubMed Trojanowski JQ, Dickson D: Update on the neuropathological diagnosis of frontotemporal dementias. J Neuropathol Exp Neurol. 2001, 60: 1123-1126.PubMed
7.
go back to reference Balch WE, Morimoto RI, Dillin A, Kelly JW: Adapting proteostasis for disease intervention. Science. 2008, 319: 916-919. 10.1126/science.1141448.CrossRefPubMed Balch WE, Morimoto RI, Dillin A, Kelly JW: Adapting proteostasis for disease intervention. Science. 2008, 319: 916-919. 10.1126/science.1141448.CrossRefPubMed
8.
go back to reference Mawuenyega KG, Sigurdson W, Ovod V, Munsell L, Kasten T, Morris JC, Yarasheski KE, Bateman RJ: Decreased clearance of CNS beta-amyloid in Alzheimer’s disease. Science. 2010, 330: 1774-10.1126/science.1197623.PubMedCentralCrossRefPubMed Mawuenyega KG, Sigurdson W, Ovod V, Munsell L, Kasten T, Morris JC, Yarasheski KE, Bateman RJ: Decreased clearance of CNS beta-amyloid in Alzheimer’s disease. Science. 2010, 330: 1774-10.1126/science.1197623.PubMedCentralCrossRefPubMed
9.
go back to reference Wolfe RR, Chinkes DL: Isotope tracers in metabolic research : principles and practice of kinetic analysis. 2005, Wiley-Liss, Hoboken, 2 Wolfe RR, Chinkes DL: Isotope tracers in metabolic research : principles and practice of kinetic analysis. 2005, Wiley-Liss, Hoboken, 2
10.
go back to reference Aebersold R, Mann M: Mass spectrometry-based proteomics. Nature. 2003, 422: 198-207. 10.1038/nature01511.CrossRefPubMed Aebersold R, Mann M: Mass spectrometry-based proteomics. Nature. 2003, 422: 198-207. 10.1038/nature01511.CrossRefPubMed
11.
go back to reference Pratt JM, Petty J, Riba-Garcia I, Robertson DH, Gaskell SJ, Oliver SG, Beynon RJ: Dynamics of protein turnover, a missing dimension in proteomics. Mol Cell Proteomics. 2002, 1: 579-591. 10.1074/mcp.M200046-MCP200.CrossRefPubMed Pratt JM, Petty J, Riba-Garcia I, Robertson DH, Gaskell SJ, Oliver SG, Beynon RJ: Dynamics of protein turnover, a missing dimension in proteomics. Mol Cell Proteomics. 2002, 1: 579-591. 10.1074/mcp.M200046-MCP200.CrossRefPubMed
12.
go back to reference Doherty MK, Hammond DE, Clague MJ, Gaskell SJ, Beynon RJ: Turnover of the human proteome: determination of protein intracellular stability by dynamic SILAC. J Proteome Res. 2009, 8: 104-112. 10.1021/pr800641v.CrossRefPubMed Doherty MK, Hammond DE, Clague MJ, Gaskell SJ, Beynon RJ: Turnover of the human proteome: determination of protein intracellular stability by dynamic SILAC. J Proteome Res. 2009, 8: 104-112. 10.1021/pr800641v.CrossRefPubMed
13.
go back to reference Schwanhausser B, Gossen M, Dittmar G, Selbach M: Global analysis of cellular protein translation by pulsed SILAC. Proteomics. 2009, 9: 205-209. 10.1002/pmic.200800275.CrossRefPubMed Schwanhausser B, Gossen M, Dittmar G, Selbach M: Global analysis of cellular protein translation by pulsed SILAC. Proteomics. 2009, 9: 205-209. 10.1002/pmic.200800275.CrossRefPubMed
14.
go back to reference Doherty MK, Whitehead C, McCormack H, Gaskell SJ, Beynon RJ: Proteome dynamics in complex organisms: using stable isotopes to monitor individual protein turnover rates. Proteomics. 2005, 5: 522-533. 10.1002/pmic.200400959.CrossRefPubMed Doherty MK, Whitehead C, McCormack H, Gaskell SJ, Beynon RJ: Proteome dynamics in complex organisms: using stable isotopes to monitor individual protein turnover rates. Proteomics. 2005, 5: 522-533. 10.1002/pmic.200400959.CrossRefPubMed
15.
go back to reference Price JC, Guan S, Burlingame A, Prusiner SB, Ghaemmaghami S: Analysis of proteome dynamics in the mouse brain. Proc Natl Acad Sci U S A. 2010, 107: 14508-14513. 10.1073/pnas.1006551107.PubMedCentralCrossRefPubMed Price JC, Guan S, Burlingame A, Prusiner SB, Ghaemmaghami S: Analysis of proteome dynamics in the mouse brain. Proc Natl Acad Sci U S A. 2010, 107: 14508-14513. 10.1073/pnas.1006551107.PubMedCentralCrossRefPubMed
16.
go back to reference Bateman RJ, Munsell LY, Morris JC, Swarm R, Yarasheski KE, Holtzman DM: Human amyloid-beta synthesis and clearance rates as measured in cerebrospinal fluid in vivo. Nat Med. 2006, 12: 856-861. 10.1038/nm1438.PubMedCentralCrossRefPubMed Bateman RJ, Munsell LY, Morris JC, Swarm R, Yarasheski KE, Holtzman DM: Human amyloid-beta synthesis and clearance rates as measured in cerebrospinal fluid in vivo. Nat Med. 2006, 12: 856-861. 10.1038/nm1438.PubMedCentralCrossRefPubMed
17.
go back to reference Bateman RJ, Munsell LY, Chen X, Holtzman DM, Yarasheski KE: Stable isotope labeling tandem mass spectrometry (SILT) to quantify protein production and clearance rates. J Am Soc Mass Spectrom. 2007, 18: 997-1006. 10.1016/j.jasms.2007.02.009.PubMedCentralCrossRefPubMed Bateman RJ, Munsell LY, Chen X, Holtzman DM, Yarasheski KE: Stable isotope labeling tandem mass spectrometry (SILT) to quantify protein production and clearance rates. J Am Soc Mass Spectrom. 2007, 18: 997-1006. 10.1016/j.jasms.2007.02.009.PubMedCentralCrossRefPubMed
18.
go back to reference Bateman RJ, Siemers ER, Mawuenyega KG, Wen G, Browning KR, Sigurdson WC, Yarasheski KE, Friedrich SW, Demattos RB, May PC, et al: A gamma-secretase inhibitor decreases amyloid-beta production in the central nervous system. Ann Neurol. 2009, 66: 48-54. 10.1002/ana.21623.PubMedCentralCrossRefPubMed Bateman RJ, Siemers ER, Mawuenyega KG, Wen G, Browning KR, Sigurdson WC, Yarasheski KE, Friedrich SW, Demattos RB, May PC, et al: A gamma-secretase inhibitor decreases amyloid-beta production in the central nervous system. Ann Neurol. 2009, 66: 48-54. 10.1002/ana.21623.PubMedCentralCrossRefPubMed
19.
go back to reference Mahley RW: Apolipoprotein E: cholesterol transport protein with expanding role in cell biology. Science. 1988, 240: 622-630. 10.1126/science.3283935.CrossRefPubMed Mahley RW: Apolipoprotein E: cholesterol transport protein with expanding role in cell biology. Science. 1988, 240: 622-630. 10.1126/science.3283935.CrossRefPubMed
20.
21.
go back to reference Deane R, Sagare A, Hamm K, Parisi M, Lane S, Finn MB, Holtzman DM, Zlokovic BV: ApoE isoform-specific disruption of amyloid beta peptide clearance from mouse brain. J Clin Invest. 2008, 118: 4002-4013. 10.1172/JCI36663.PubMedCentralCrossRefPubMed Deane R, Sagare A, Hamm K, Parisi M, Lane S, Finn MB, Holtzman DM, Zlokovic BV: ApoE isoform-specific disruption of amyloid beta peptide clearance from mouse brain. J Clin Invest. 2008, 118: 4002-4013. 10.1172/JCI36663.PubMedCentralCrossRefPubMed
22.
go back to reference Castellano JM, Kim J, Stewart FR, Jiang H, Demattos RB, Patterson BW, Fagan AM, Morris JC, Mawuenyega KG, Cruchaga C, et al: Human apoE Isoforms Differentially Regulate Brain Amyloid-{beta} Peptide Clearance. Sci Transl Med. 2011, 3: 89ra57-10.1126/scitranslmed.3002156.PubMedCentralPubMed Castellano JM, Kim J, Stewart FR, Jiang H, Demattos RB, Patterson BW, Fagan AM, Morris JC, Mawuenyega KG, Cruchaga C, et al: Human apoE Isoforms Differentially Regulate Brain Amyloid-{beta} Peptide Clearance. Sci Transl Med. 2011, 3: 89ra57-10.1126/scitranslmed.3002156.PubMedCentralPubMed
23.
go back to reference Ma J, Yee A, Brewer HB: Das S, Potter H: Amyloid-associated proteins alpha 1-antichymotrypsin and apolipoprotein E promote assembly of Alzheimer beta-protein into filaments. Nature. 1994, 372: 92-94. 10.1038/372092a0.CrossRefPubMed Ma J, Yee A, Brewer HB: Das S, Potter H: Amyloid-associated proteins alpha 1-antichymotrypsin and apolipoprotein E promote assembly of Alzheimer beta-protein into filaments. Nature. 1994, 372: 92-94. 10.1038/372092a0.CrossRefPubMed
24.
go back to reference Evans KC, Berger EP, Cho CG, Weisgraber KH, Lansbury PT: Apolipoprotein E is a kinetic but not a thermodynamic inhibitor of amyloid formation: implications for the pathogenesis and treatment of Alzheimer disease. Proc Natl Acad Sci U S A. 1995, 92: 763-767. 10.1073/pnas.92.3.763.PubMedCentralCrossRefPubMed Evans KC, Berger EP, Cho CG, Weisgraber KH, Lansbury PT: Apolipoprotein E is a kinetic but not a thermodynamic inhibitor of amyloid formation: implications for the pathogenesis and treatment of Alzheimer disease. Proc Natl Acad Sci U S A. 1995, 92: 763-767. 10.1073/pnas.92.3.763.PubMedCentralCrossRefPubMed
25.
go back to reference Bales KR, Verina T, Dodel RC, Du Y, Altstiel L, Bender M, Hyslop P, Johnstone EM, Little SP, Cummins DJ, et al: Lack of apolipoprotein E dramatically reduces amyloid beta-peptide deposition. Nat Genet. 1997, 17: 263-264. 10.1038/ng1197-263.CrossRefPubMed Bales KR, Verina T, Dodel RC, Du Y, Altstiel L, Bender M, Hyslop P, Johnstone EM, Little SP, Cummins DJ, et al: Lack of apolipoprotein E dramatically reduces amyloid beta-peptide deposition. Nat Genet. 1997, 17: 263-264. 10.1038/ng1197-263.CrossRefPubMed
26.
go back to reference Kim J, Jiang H, Park S, Eltorai AE, Stewart FR, Yoon H, Basak JM, Finn MB, Holtzman DM: Haploinsufficiency of human APOE reduces amyloid deposition in a mouse model of amyloid-beta amyloidosis. J Neurosci. 2011, 31: 18007-18012. 10.1523/JNEUROSCI.3773-11.2011.PubMedCentralCrossRefPubMed Kim J, Jiang H, Park S, Eltorai AE, Stewart FR, Yoon H, Basak JM, Finn MB, Holtzman DM: Haploinsufficiency of human APOE reduces amyloid deposition in a mouse model of amyloid-beta amyloidosis. J Neurosci. 2011, 31: 18007-18012. 10.1523/JNEUROSCI.3773-11.2011.PubMedCentralCrossRefPubMed
27.
go back to reference Kim J, Castellano JM, Jiang H, Basak JM, Parsadanian M, Pham V, Mason SM, Paul SM, Holtzman DM: Overexpression of low-density lipoprotein receptor in the brain markedly inhibits amyloid deposition and increases extracellular A beta clearance. Neuron. 2009, 64: 632-644. 10.1016/j.neuron.2009.11.013.PubMedCentralCrossRefPubMed Kim J, Castellano JM, Jiang H, Basak JM, Parsadanian M, Pham V, Mason SM, Paul SM, Holtzman DM: Overexpression of low-density lipoprotein receptor in the brain markedly inhibits amyloid deposition and increases extracellular A beta clearance. Neuron. 2009, 64: 632-644. 10.1016/j.neuron.2009.11.013.PubMedCentralCrossRefPubMed
28.
go back to reference Wahrle SE, Jiang H, Parsadanian M, Legleiter J, Han X, Fryer JD, Kowalewski T, Holtzman DM: ABCA1 is required for normal central nervous system ApoE levels and for lipidation of astrocyte-secreted apoE. J Biol Chem. 2004, 279: 40987-40993. 10.1074/jbc.M407963200.CrossRefPubMed Wahrle SE, Jiang H, Parsadanian M, Legleiter J, Han X, Fryer JD, Kowalewski T, Holtzman DM: ABCA1 is required for normal central nervous system ApoE levels and for lipidation of astrocyte-secreted apoE. J Biol Chem. 2004, 279: 40987-40993. 10.1074/jbc.M407963200.CrossRefPubMed
29.
go back to reference Hirsch-Reinshagen V, Zhou S, Burgess BL, Bernier L, McIsaac SA, Chan JY, Tansley GH, Cohn JS, Hayden MR, Wellington CL: Deficiency of ABCA1 impairs apolipoprotein E metabolism in brain. J Biol Chem. 2004, 279: 41197-41207. 10.1074/jbc.M407962200.CrossRefPubMed Hirsch-Reinshagen V, Zhou S, Burgess BL, Bernier L, McIsaac SA, Chan JY, Tansley GH, Cohn JS, Hayden MR, Wellington CL: Deficiency of ABCA1 impairs apolipoprotein E metabolism in brain. J Biol Chem. 2004, 279: 41197-41207. 10.1074/jbc.M407962200.CrossRefPubMed
30.
go back to reference Wahrle SE, Jiang H, Parsadanian M, Kim J, Li A, Knoten A, Jain S, Hirsch-Reinshagen V, Wellington CL, Bales KR, et al: Overexpression of ABCA1 reduces amyloid deposition in the PDAPP mouse model of Alzheimer disease. J Clin Invest. 2008, 118: 671-682.PubMedCentralPubMed Wahrle SE, Jiang H, Parsadanian M, Kim J, Li A, Knoten A, Jain S, Hirsch-Reinshagen V, Wellington CL, Bales KR, et al: Overexpression of ABCA1 reduces amyloid deposition in the PDAPP mouse model of Alzheimer disease. J Clin Invest. 2008, 118: 671-682.PubMedCentralPubMed
31.
go back to reference Garlick PJ, McNurlan MA, Essen P, Wernerman J: Measurement of tissue protein synthesis rates in vivo: a critical analysis of contrasting methods. Am J Physiol. 1994, 266: E287-E297.PubMed Garlick PJ, McNurlan MA, Essen P, Wernerman J: Measurement of tissue protein synthesis rates in vivo: a critical analysis of contrasting methods. Am J Physiol. 1994, 266: E287-E297.PubMed
32.
go back to reference Imoberdorf R, Garlick PJ, McNurlan MA, Casella GA, Peheim E, Turgay M, Bartsch P, Ballmer PE: Enhanced synthesis of albumin and fibrinogen at high altitude. J Appl Physiol. 2001, 90: 528-537.PubMed Imoberdorf R, Garlick PJ, McNurlan MA, Casella GA, Peheim E, Turgay M, Bartsch P, Ballmer PE: Enhanced synthesis of albumin and fibrinogen at high altitude. J Appl Physiol. 2001, 90: 528-537.PubMed
33.
go back to reference Zhang XJ, Chinkes DL, Wolfe RR: Measurement of muscle protein fractional synthesis and breakdown rates from a pulse tracer injection. Am J Physiol Endocrinol Metab. 2002, 283: E753-E764.CrossRefPubMed Zhang XJ, Chinkes DL, Wolfe RR: Measurement of muscle protein fractional synthesis and breakdown rates from a pulse tracer injection. Am J Physiol Endocrinol Metab. 2002, 283: E753-E764.CrossRefPubMed
34.
go back to reference Smith QR, Momma S, Aoyagi M, Rapoport SI: Kinetics of neutral amino acid transport across the blood–brain barrier. J Neurochem. 1987, 49: 1651-1658. 10.1111/j.1471-4159.1987.tb01039.x.CrossRefPubMed Smith QR, Momma S, Aoyagi M, Rapoport SI: Kinetics of neutral amino acid transport across the blood–brain barrier. J Neurochem. 1987, 49: 1651-1658. 10.1111/j.1471-4159.1987.tb01039.x.CrossRefPubMed
35.
go back to reference Ong SE, Blagoev B, Kratchmarova I, Kristensen DB, Steen H, Pandey A, Mann M: Stable isotope labeling by amino acids in cell culture, SILAC, as a simple and accurate approach to expression proteomics. Mol Cell Proteomics. 2002, 1: 376-386. 10.1074/mcp.M200025-MCP200.CrossRefPubMed Ong SE, Blagoev B, Kratchmarova I, Kristensen DB, Steen H, Pandey A, Mann M: Stable isotope labeling by amino acids in cell culture, SILAC, as a simple and accurate approach to expression proteomics. Mol Cell Proteomics. 2002, 1: 376-386. 10.1074/mcp.M200025-MCP200.CrossRefPubMed
36.
go back to reference Lusis AJ, Taylor BA, Quon D, Zollman S, LeBoeuf RC: Genetic factors controlling structure and expression of apolipoproteins B and E in mice. J Biol Chem. 1987, 262: 7594-7604.PubMed Lusis AJ, Taylor BA, Quon D, Zollman S, LeBoeuf RC: Genetic factors controlling structure and expression of apolipoproteins B and E in mice. J Biol Chem. 1987, 262: 7594-7604.PubMed
37.
go back to reference Srivastava RA, Krul ES, Lin RC, Schonfeld G: Regulation of lipoprotein metabolism by estrogen in inbred strains of mice occurs primarily by posttranscriptional mechanisms. Mol Cell Biochem. 1997, 173: 161-168. 10.1023/A:1006896131186.CrossRefPubMed Srivastava RA, Krul ES, Lin RC, Schonfeld G: Regulation of lipoprotein metabolism by estrogen in inbred strains of mice occurs primarily by posttranscriptional mechanisms. Mol Cell Biochem. 1997, 173: 161-168. 10.1023/A:1006896131186.CrossRefPubMed
38.
go back to reference Brown MS, Goldstein JL: A receptor-mediated pathway for cholesterol homeostasis. Science. 1986, 232: 34-47. 10.1126/science.3513311.CrossRefPubMed Brown MS, Goldstein JL: A receptor-mediated pathway for cholesterol homeostasis. Science. 1986, 232: 34-47. 10.1126/science.3513311.CrossRefPubMed
39.
go back to reference Lawn RM, Wade DP, Garvin MR, Wang X, Schwartz K, Porter JG, Seilhamer JJ, Vaughan AM, Oram JF: The Tangier disease gene product ABC1 controls the cellular apolipoprotein-mediated lipid removal pathway. J Clin Invest. 1999, 104: R25-R31. 10.1172/JCI8119.PubMedCentralCrossRefPubMed Lawn RM, Wade DP, Garvin MR, Wang X, Schwartz K, Porter JG, Seilhamer JJ, Vaughan AM, Oram JF: The Tangier disease gene product ABC1 controls the cellular apolipoprotein-mediated lipid removal pathway. J Clin Invest. 1999, 104: R25-R31. 10.1172/JCI8119.PubMedCentralCrossRefPubMed
40.
go back to reference Hirsch-Reinshagen V, Maia LF, Burgess BL, Blain JF, Naus KE, McIsaac SA, Parkinson PF, Chan JY, Tansley GH, Hayden MR, et al: The absence of ABCA1 decreases soluble ApoE levels but does not diminish amyloid deposition in two murine models of Alzheimer disease. J Biol Chem. 2005, 280: 43243-43256. 10.1074/jbc.M508781200.CrossRefPubMed Hirsch-Reinshagen V, Maia LF, Burgess BL, Blain JF, Naus KE, McIsaac SA, Parkinson PF, Chan JY, Tansley GH, Hayden MR, et al: The absence of ABCA1 decreases soluble ApoE levels but does not diminish amyloid deposition in two murine models of Alzheimer disease. J Biol Chem. 2005, 280: 43243-43256. 10.1074/jbc.M508781200.CrossRefPubMed
41.
go back to reference Koldamova R, Staufenbiel M, Lefterov I: Lack of ABCA1 considerably decreases brain ApoE level and increases amyloid deposition in APP23 mice. J Biol Chem. 2005, 280: 43224-43235. 10.1074/jbc.M504513200.CrossRefPubMed Koldamova R, Staufenbiel M, Lefterov I: Lack of ABCA1 considerably decreases brain ApoE level and increases amyloid deposition in APP23 mice. J Biol Chem. 2005, 280: 43224-43235. 10.1074/jbc.M504513200.CrossRefPubMed
42.
go back to reference Wahrle SE, Jiang H, Parsadanian M, Hartman RE, Bales KR, Paul SM, Holtzman DM: Deletion of Abca1 increases Abeta deposition in the PDAPP transgenic mouse model of Alzheimer disease. J Biol Chem. 2005, 280: 43236-43242. 10.1074/jbc.M508780200.CrossRefPubMed Wahrle SE, Jiang H, Parsadanian M, Hartman RE, Bales KR, Paul SM, Holtzman DM: Deletion of Abca1 increases Abeta deposition in the PDAPP transgenic mouse model of Alzheimer disease. J Biol Chem. 2005, 280: 43236-43242. 10.1074/jbc.M508780200.CrossRefPubMed
43.
go back to reference Hirsch-Reinshagen V, Wellington CL: Cholesterol metabolism, apolipoprotein E, adenosine triphosphate-binding cassette transporters, and Alzheimer’s disease. Curr Opin Lipidol. 2007, 18: 325-332. 10.1097/MOL.0b013e32813aeabf.CrossRefPubMed Hirsch-Reinshagen V, Wellington CL: Cholesterol metabolism, apolipoprotein E, adenosine triphosphate-binding cassette transporters, and Alzheimer’s disease. Curr Opin Lipidol. 2007, 18: 325-332. 10.1097/MOL.0b013e32813aeabf.CrossRefPubMed
44.
go back to reference Schaefer EJ, Anderson DW, Zech LA, Lindgren FT, Bronzert TB, Rubalcaba EA, Brewer HB: Metabolism of high density lipoprotein subfractions and constituents in Tangier disease following the infusion of high density lipoproteins. J Lipid Res. 1981, 22: 217-228.PubMed Schaefer EJ, Anderson DW, Zech LA, Lindgren FT, Bronzert TB, Rubalcaba EA, Brewer HB: Metabolism of high density lipoprotein subfractions and constituents in Tangier disease following the infusion of high density lipoproteins. J Lipid Res. 1981, 22: 217-228.PubMed
45.
go back to reference Schaefer EJ, Brousseau ME, Diffenderfer MR, Cohn JS, Welty FK, O’Connor J: Dolnikowski GG, Wang J, Hegele RA, Jones PJ: Cholesterol and apolipoprotein B metabolism in Tangier disease. Atherosclerosis. 2001, 159: 231-236. 10.1016/S0021-9150(01)00688-8.CrossRefPubMed Schaefer EJ, Brousseau ME, Diffenderfer MR, Cohn JS, Welty FK, O’Connor J: Dolnikowski GG, Wang J, Hegele RA, Jones PJ: Cholesterol and apolipoprotein B metabolism in Tangier disease. Atherosclerosis. 2001, 159: 231-236. 10.1016/S0021-9150(01)00688-8.CrossRefPubMed
46.
go back to reference Innerarity TL, Mahley RW: Enhanced binding by cultured human fibroblasts of apo-E-containing lipoproteins as compared with low density lipoproteins. Biochemistry. 1978, 17: 1440-1447. 10.1021/bi00601a013.CrossRefPubMed Innerarity TL, Mahley RW: Enhanced binding by cultured human fibroblasts of apo-E-containing lipoproteins as compared with low density lipoproteins. Biochemistry. 1978, 17: 1440-1447. 10.1021/bi00601a013.CrossRefPubMed
47.
go back to reference Akanuma S, Ohtsuki S, Doi Y, Tachikawa M, Ito S, Hori S, Asashima T, Hashimoto T, Yamada K, Ueda K, et al: ATP-binding cassette transporter A1 (ABCA1) deficiency does not attenuate the brain-to-blood efflux transport of human amyloid-beta peptide (1–40) at the blood–brain barrier. Neurochem Int. 2008, 52: 956-961. 10.1016/j.neuint.2007.12.002.CrossRefPubMed Akanuma S, Ohtsuki S, Doi Y, Tachikawa M, Ito S, Hori S, Asashima T, Hashimoto T, Yamada K, Ueda K, et al: ATP-binding cassette transporter A1 (ABCA1) deficiency does not attenuate the brain-to-blood efflux transport of human amyloid-beta peptide (1–40) at the blood–brain barrier. Neurochem Int. 2008, 52: 956-961. 10.1016/j.neuint.2007.12.002.CrossRefPubMed
48.
go back to reference Savage MJ, Trusko SP, Howland DS, Pinsker LR, Mistretta S, Reaume AG, Greenberg BD, Siman R, Scott RW: Turnover of amyloid beta-protein in mouse brain and acute reduction of its level by phorbol ester. J Neurosci. 1998, 18: 1743-1752.PubMed Savage MJ, Trusko SP, Howland DS, Pinsker LR, Mistretta S, Reaume AG, Greenberg BD, Siman R, Scott RW: Turnover of amyloid beta-protein in mouse brain and acute reduction of its level by phorbol ester. J Neurosci. 1998, 18: 1743-1752.PubMed
49.
go back to reference Cirrito JR, May PC, O’Dell MA, Taylor JW, Parsadanian M, Cramer JW, Audia JE, Nissen JS, Bales KR, Paul SM, et al: In vivo assessment of brain interstitial fluid with microdialysis reveals plaque-associated changes in amyloid-beta metabolism and half-life. J Neurosci. 2003, 23: 8844-8853.PubMed Cirrito JR, May PC, O’Dell MA, Taylor JW, Parsadanian M, Cramer JW, Audia JE, Nissen JS, Bales KR, Paul SM, et al: In vivo assessment of brain interstitial fluid with microdialysis reveals plaque-associated changes in amyloid-beta metabolism and half-life. J Neurosci. 2003, 23: 8844-8853.PubMed
50.
go back to reference Barten DM, Guss VL, Corsa JA, Loo A, Hansel SB, Zheng M, Munoz B, Srinivasan K, Wang B, Robertson BJ, et al: Dynamics of {beta}-amyloid reductions in brain, cerebrospinal fluid, and plasma of {beta}-amyloid precursor protein transgenic mice treated with a {gamma}-secretase inhibitor. J Pharmacol Exp Ther. 2005, 312: 635-643.CrossRefPubMed Barten DM, Guss VL, Corsa JA, Loo A, Hansel SB, Zheng M, Munoz B, Srinivasan K, Wang B, Robertson BJ, et al: Dynamics of {beta}-amyloid reductions in brain, cerebrospinal fluid, and plasma of {beta}-amyloid precursor protein transgenic mice treated with a {gamma}-secretase inhibitor. J Pharmacol Exp Ther. 2005, 312: 635-643.CrossRefPubMed
51.
go back to reference Abramowski D, Wiederhold KH, Furrer U, Jaton AL, Neuenschwander A, Runser MJ, Danner S, Reichwald J, Ammaturo D, Staab D, et al: Dynamics of Abeta turnover and deposition in different beta-amyloid precursor protein transgenic mouse models following gamma-secretase inhibition. J Pharmacol Exp Ther. 2008, 327: 411-424. 10.1124/jpet.108.140327.CrossRefPubMed Abramowski D, Wiederhold KH, Furrer U, Jaton AL, Neuenschwander A, Runser MJ, Danner S, Reichwald J, Ammaturo D, Staab D, et al: Dynamics of Abeta turnover and deposition in different beta-amyloid precursor protein transgenic mouse models following gamma-secretase inhibition. J Pharmacol Exp Ther. 2008, 327: 411-424. 10.1124/jpet.108.140327.CrossRefPubMed
52.
go back to reference Patterson BW, Carraro F, Wolfe RR: Measurement of 15 N enrichment in multiple amino acids and urea in a single analysis by gas chromatography/mass spectrometry. Biol Mass Spectrom. 1993, 22: 518-523. 10.1002/bms.1200220905.CrossRefPubMed Patterson BW, Carraro F, Wolfe RR: Measurement of 15 N enrichment in multiple amino acids and urea in a single analysis by gas chromatography/mass spectrometry. Biol Mass Spectrom. 1993, 22: 518-523. 10.1002/bms.1200220905.CrossRefPubMed
53.
go back to reference Patterson BW, Mittendorfer B, Elias N, Satyanarayana R, Klein S: Use of stable isotopically labeled tracers to measure very low density lipoprotein-triglyceride turnover. J Lipid Res. 2002, 43: 223-233.PubMed Patterson BW, Mittendorfer B, Elias N, Satyanarayana R, Klein S: Use of stable isotopically labeled tracers to measure very low density lipoprotein-triglyceride turnover. J Lipid Res. 2002, 43: 223-233.PubMed
Metadata
Title
Measurement of apolipoprotein E and amyloid β clearance rates in the mouse brain using bolus stable isotope labeling
Authors
Jacob M Basak
Jungsu Kim
Yuriy Pyatkivskyy
Kristin R Wildsmith
Hong Jiang
Maia Parsadanian
Bruce W Patterson
Randall J Bateman
David M Holtzman
Publication date
01-12-2012
Publisher
BioMed Central
Published in
Molecular Neurodegeneration / Issue 1/2012
Electronic ISSN: 1750-1326
DOI
https://doi.org/10.1186/1750-1326-7-14

Other articles of this Issue 1/2012

Molecular Neurodegeneration 1/2012 Go to the issue